707
Views
4
CrossRef citations to date
0
Altmetric
Articles

Omalizumab in non-allergic Asthma: A report of 13 cases

, MD, , MD, , MD ORCID Icon, , MD, , MD, , MD, , MD & , MD show all
Pages 756-763 | Received 19 Apr 2017, Accepted 27 Jul 2017, Published online: 12 Sep 2017

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Didier Cataldo, Renaud Louis, Alain Michils, Rudi Peché, Charles Pilette, Florence Schleich, Vincent Ninane & Shane Hanon. (2021) Severe asthma: oral corticosteroid alternatives and the need for optimal referral pathways. Journal of Asthma 58:4, pages 448-458.
Read now

Articles from other publishers (3)

Philippe Gevaert, Kit Wong, Lauren A. Millette & Tara F. Carr. (2021) The Role of IgE in Upper and Lower Airway Disease: More Than Just Allergy!. Clinical Reviews in Allergy & Immunology 62:1, pages 200-215.
Crossref
Paloma Campo, Gregorio Soto Campos, Ana Moreira, Santiago Quirce, Alicia Padilla‐Galo, Eva Martínez‐Moragón, Aizea Mardones & Ignacio Dávila. (2020) Real‐life study in non‐atopic severe asthma patients achieving disease control by omalizumab treatment. Allergy 76:6, pages 1868-1872.
Crossref
Tuba Erdogan. (2020) Evaluating nonadherence to preventer inhaler therapy in severe asthmatic patients receiving omalizumab. The Clinical Respiratory Journal 14:12, pages 1153-1158.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.